It’s up to pharma
Tomorrow we’ll begin to learn more about just how bad things have become in the digital health arena when Teladoc reports second quarter results. As we have noted the company has already telegraphed in previous comments that the results will be less than stellular. The stock continues to fall as the entire digital world is scrambling to remain relevant now that the people are going back to their doctor’s office.
While we doubt the folk at Teladoc, or any digital player is hoping that the Delta variant gets worse the variant does point to the need for digital . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.